This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alkermes (ALKS) in Focus: Stock Moves 11.1% Higher
by Zacks Equity Research
Alkermes plc (ALKS) saw its shares rise over 11% on the day.
Allergan's (AGN) Vraylar Gets RTF From FDA, New Data for CVC
by Zacks Equity Research
The FDA slaps a refusal-to-file letter on Allergan's (AGN) Vraylar for its supplemental New Drug Application. The company tries to expand the drug???s label for its use as a maintenance treatment.
Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia
by Zacks Equity Research
Alkermes (ALKS) announced encouraging results from a phase IV study of ARISTADA for the treatment of schizophrenia.
Biotech Stock Roundup: EU Label Expansion for Alexion, BIIB Facing Drug Price Probe
by Arpita Dutt
Key highlights include regulatory approvals for companies like Alexion (ALXN) and Ironwood while Biogen is one of the companies facing an investigation into the pricing of multiple sclerosis drugs.
Alkermes Initiates Rolling Submission of Depression Drug
by Zacks Equity Research
Alkermes (ALKS) initiated the rolling submission of a New Drug Application (NDA) to the FDA for pipeline candidate ALKS 5461 for major depressive disorder.
What You See, and What You Get: The Neurology of Perception
by Kevin Cook
While "the biotech century" cures cancer, it's also tackling dozens of neurological diseases investors should learn about.
Alkermes (ALKS) Q2 Loss Narrower than Expected, Sales Beat
by Zacks Equity Research
Alkermes plc (ALKS) incurred narrower than expected loss in Q2 but marginally surpassed sales estimates. The company reiterated its 2017 outlook.
Biotech Stock Roundup: Cara Plunges on Study Data, Regulatory Updates & More
by Arpita Dutt
Key highlights in the biotech sector include mixed data from Cara (CARA) and regulatory updates from companies like BioMarin.
Alkermes Presents Phase III Data on Schizophrenia Candidate
by Zacks Equity Research
Alkermes plc (ALKS) announced positive preliminary top-line results from a phase III study, ENLIGHTEN-1, evaluating its schizophrenia candidate, ALKS 3831.
Minerva On Track to Initiate Phase III Schizophrenia Study
by Zacks Equity Research
Minerva Neurosciences, Inc. (NERV) announced that it is on track to begin phase III studies on its key schizophrenia pipeline candidate MIN-101 in the second half of this year, as planned.
Alkermes Commences Phase III Study for Schizophrenia Drug
by Zacks Equity Research
Alkermes plc (ALKS) announced that it initiated a phase III study, ENLIGHTEN-Early on experimental candidate, ALKS 3831.
Alkermes Gets FDA Nod for Two Month Dose of Aristada
by Zacks Equity Research
Alkermes plc (ALKS) announced that the FDA has approved two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.
Key FDA Events to Watch Out for in Jun 2017
by Arpita Dutt
Companies like Portola (PTLA) are awaiting key FDA decisions this month which could send their stocks soaring in case of a positive response.
Alkermes (ALKS) Up 2.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alkermes (ALKS) Q1 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
Alkermes plc (ALKS) reported loss of 31 cents per share (including the impact of share-based compensation expense) in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 24 cents.
5 Drug Stocks for Your Portfolio this World Health Day
by Arpita Dutt
With "Depression: let's talk" being this year's World Health Day campaign slogan, here's a look at 5 companies developing treatments for various types of depression.
Alkermes Starts Phase III Study to Treat Multiple Sclerosis
by Zacks Equity Research
Alkermes plc (ALKS) announced the initiation of a new phase III study of pipeline candidate ALKS 8700.
Allergan's (AGN) Vraylar sNDA Accepted for Review by FDA
by Zacks Equity Research
Allergan plc (AGN) announced that its supplemental New Drug Application (sNDA) for its schizophrenia capsules Vraylar has been accepted for review by the FDA.
Alkermes (ALKS) Q4 Loss Narrower than Expectations, Sales Beat
by Zacks Equity Research
Alkermes plc (ALKS) reported loss of 4 cents per share (including the impact of share-based compensation expense) in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 19 cents.
5 Drug Stocks to Avoid as Trump Vows to Lower Drug Prices
by Zacks Equity Research
For those who thought that the pharma/biotech sector is in for an extraordinary run after Donald Trump's unexpected victory, his latest vow to crack down on excessive drug price hikes comes as a bolt from the blue.